{"id":544060,"date":"2026-08-06T06:12:24","date_gmt":"2026-08-06T06:12:24","guid":{"rendered":"https:\/\/www.newjerseyheadlines.com\/news\/story\/544060\/creative-biolabs-expands-aidriven-antibody-discovery-portfolio.html"},"modified":"2026-08-06T06:12:24","modified_gmt":"2026-08-06T06:12:24","slug":"creative-biolabs-expands-aidriven-antibody-discovery-portfolio","status":"publish","type":"post","link":"http:\/\/www.northcarolinaheadlines.com\/news\/story\/544060\/creative-biolabs-expands-aidriven-antibody-discovery-portfolio.html","title":{"rendered":"Creative Biolabs Expands AI-Driven Antibody Discovery Portfolio"},"content":{"rendered":"
Integrated protein modeling, motion simulation, and AI-driven HTS screening help research teams prioritize preclinical antibody candidates and evaluate developability early.<\/div>\n

New York, USA – August 6, 2026 –<\/strong> As biopharmaceutical research targets complex disease mechanisms—such as multi-pass membrane proteins, transient protein-protein interactions (PPIs), and cryptic epitopes—traditional empirical screening often faces high attrition rates and extended timelines. Early-stage decisions frequently rely on limited structural data, increasing the risk of downstream developability failures.<\/p>\n

\"\"<\/p>\n

To address these preclinical bottlenecks, Creative Biolabs has expanded its computational biology capabilities into a unified AI-driven antibody discovery framework. By integrating primary sequence analysis, 3D structural prediction, conformational dynamics, and in silico<\/em> developability profiling, the platform provides biopharma researchers with actionable hypotheses to prioritize lead candidates before committing to resource-intensive laboratory assays.<\/p>\n

AI-Driven Protein Modeling for Structure-Based Discovery<\/strong><\/p>\n

At the foundation of the expanded portfolio is the AI-driven protein modeling service<\/a>, which translates primary amino acid sequences into predicted three-dimensional coordinates.<\/p>\n

Built upon deep-learning architectures—including graph neural networks and attention-based models inspired by AlphaFold—the service generates structural models for target antigens, antibodies, and engineered constructs. Rather than replacing X-ray crystallography or cryo-EM, computational modeling serves as a rapid prioritization layer to:<\/p>\n

Map Functional Interfaces:<\/strong> Identify putative epitope-paratope interactions and contact residues at atomic resolution.<\/p>\n

Support Structure-Guided Design:<\/strong> Enable rational mutagenesis and affinity maturation strategies without waiting for experimental structure determination.<\/p>\n

Model Complex Targets:<\/strong> Generate working structural hypotheses for challenging antigens where crystallization is technically difficult.<\/p>\n

Protein Motion Simulation for Dynamic Interaction Analysis<\/strong><\/p>\n

Because biological recognition occurs in a dynamic physiological environment, static crystal structures or consensus models can overlook critical functional states. Creative Biolabs complements static modeling with its AI-driven protein motion simulation service<\/a>.<\/p>\n

Using machine learning-enhanced force fields and coarse-grained fragmentation methods, the platform simulates conformational trajectories over biologically relevant timescales. This dynamic sampling allows researchers to:<\/p>\n

Uncover Transient States:<\/strong> Identify transiently open binding pockets, cryptic epitopes, and allosteric sites that remain hidden in static conformations.<\/p>\n

Evaluate Conformational Flexibility:<\/strong> Assess how CDR loop flexibility influences binding kinetics and target specificity.<\/p>\n

Compress Computational Sampling:<\/strong> Reduce molecular dynamics calculation times from weeks to days, enabling comparative dynamic screening across lead panels.<\/p>\n

AI-Driven HTS Smart Screening for Candidate Prioritization<\/strong><\/p>\n

To bridge atomic-level modeling with large-scale candidate selection, Creative Biolabs has deployed its AI-driven HTS smart screening service. Designed to identify sequence liabilities early in the discovery funnel, the service evaluates biophysical and biochemical profiles across antibody libraries.<\/p>\n

Trained on curated datasets of clinical and approved biotherapeutics, the platform assesses key developability parameters in silico<\/em>, including:<\/p>\n

Thermal Stability & Aggregation Propensity:<\/strong> Flagging hydrophobic patches and surface motifs associated with colloidal instability.<\/p>\n

Sequence Liabilities:<\/strong> Identifying potential deamidation, isomerization, and oxidation motifs within CDRs.<\/p>\n

Physicochemical Profiling:<\/strong> Calculating expected isoelectric point ($mathrm{pI}$), surface hydrophobicity, and potential immunogenicity risks.<\/p>\n

Candidates are benchmarked against reference therapeutic antibodies, providing teams with ranked candidate lists and specific engineering recommendations to mitigate downstream manufacturing risks.<\/p>\n

Upcoming Webinar & Preclinical Consultation<\/strong><\/p>\n

To demonstrate how integrated computational and experimental workflows are applied in active drug discovery programs, Creative Biolabs will host a live educational webinar titled “Novel Platforms for Preclinical Antibody Discovery” on August 11, 2026, at 11:00 AM EDT. Featuring Dr. Ivelin Georgiev, the session will explore practical case studies on AI-guided epitope profiling, developability triage, and bench-to-computational integration. Biopharmaceutical professionals interested in attending can register online today to reserve a virtual seat<\/a>, or contact the Creative Biolabs computational biology team directly to request a preliminary developability assessment and a customized project proposal.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs
Contact Person:<\/strong> Candy Swift
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1-631-830-6441
Country:<\/strong> United States
Website:<\/strong> https:\/\/ai.creative-biolabs.com<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Integrated protein modeling, motion simulation, and AI-driven HTS screening help research teams prioritize preclinical antibody candidates and evaluate developability early. New York, USA – August 6, 2026 – As biopharmaceutical<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/544060"}],"collection":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/comments?post=544060"}],"version-history":[{"count":0,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/544060\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/media?parent=544060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/categories?post=544060"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/tags?post=544060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}